Alterity Therapeutics (ATHE) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Alterity Therapeutics Limited has announced the issuance of unquoted equity securities under an employee incentive scheme, with a total of 209 million options to be issued, exercisable at prices ranging from USD 0.003 to AUD 0.004 and expiring in March 2029. The options, which will not be quoted on the ASX, are intended to incentivize employees and were not issued to key management personnel, except for 120 million options granted to David Stamler.
For further insights into ATHE stock, check out TipRanks’ Stock Analysis page.